Mark Schoenebaum was a brilliant and successful Wall Street research analyst who fundamentally changed the way sell-siders cover biotech stocks. More importantly, Mark was a remarkably nice guy. Wall Street is not known for warm and fuzzy people, but Mark smashed that mold. He was kind and funny. He was gregarious and uncommonly generous to colleagues, friends, and even strangers.
Most of the biotech investment community first heard about Mark’s death via a gut-wrenching email sent by his friend and former colleague Umer Raffat on Sunday evening.